DSM 265

Drug Profile

DSM 265

Alternative Names: DSM-265; PfSPZ

Latest Information Update: 19 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Monash University; University of Texas Southwestern Medical Center; University of Washington
  • Developer Center for Infectious Disease Research; Fred Hutchinson Cancer Research Center; Medicines for Malaria Venture; Takeda; United States Department of Defense
  • Class Antimalarials; Pyrimidines; Small molecules; Triazoles
  • Mechanism of Action Dihydroorotate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Malaria

Most Recent Events

  • 19 May 2017 Medicines for Malaria Venture plans a phase I trial in Healthy volunteers in Australia (ACTRN12617000711314)
  • 13 Sep 2016 Medicines for Malaria Venture and AbbVie terminate a phase I bioavailability trial in Healthy volunteers in USA (PO, Granule) (NCT02750384)
  • 01 May 2016 Medicines for Malaria Venture and AbbVie initiate a phase I bioavailability trial in Healthy volunteers in USA (PO, Granule) (NCT02750384)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top